November 16, 2023
Medical Disposables and Supplies Limited (MDS) for the six months ended September 30, 2023, reported a 2% decrease in revenue totalling $1.79 billion compared to $1.82 billion in the corresponding period last year. Revenue for the second quarter experienced a 7% decline to close at $866.95 million compared to $930.24 million for the comparable quarter of 2022.
Cost of sales amounted to $1.338 billion (2022: $1.342 billion), a marginal decrease year over year. Consequently, gross profit slipped 5% to $454.49 million compared to $480.37 million for the six months ended September 30, 2022. MDS booked gross profit of $219.82 million for the second quarter versus $250.93 million reported for the similar quarter of 2022.
Total operating expenses for the six months ended September 30, 2023, amounted to $425.65 million, a 9% increase relative to $391.42 million reported in 2022. This was primarily due to administrative expenses, which increased by 17%, closing at $251.62 million (2022: $215.74 million). Notably, selling and promotional costs fell 3% from $157.95 million in 2022 to $153.20 million for the period under review.
Operating profit for the six months ended September 30, 2023, amounted to $34.30 million, a 64% decline relative to $94.01 million reported in 2022. MDS reported operating profit for the second quarter of $8.87 million (2022: $49.21 million).
Year to date, finance income decreased by 95% to close at $96,957 (2022: $2.06 million), while finance costs climbed by 34% to totalled $70.59 million (2022: $52.62 million).
Loss before tax for the six months ended September 30, 2023, amounted to $39.96 million relative to a profit of $43.83 million reported in 2022. Loss before tax for the second quarter amounted to $38.28 million in contrast to a profit of $23.99 million documented in 2022. The Company recorded a tax credit for the six months which amounted to $181,742 compared to a tax charge of $7.98 million for 2022. Consequently, net loss for the six months period amounted to $39.77 million relative to a profit of $35.85 million reported in 2022. For the second quarter, MDS recorded a net loss of $38.28 million versus a profit of $19.30 million recorded twelve months earlier.
Loss per share (LPS) for the six months amounted to $0.15 (2022: EPS of $0.14), while LPS for the quarter totalled $0.15 (2022: EPS of $0.07). The twelve-month trailing EPS was $0.01, and the number of shares used in these calculations was 263,157,895.
Notably, MDS’s stock price closed the trading period on November 15, 2023 at a price of $3.37.
Balance Sheet Highlights:
The Company’s assets totalled $2.98 billion; a 2% increase from $2.91 billion booked in 2022.
Shareholder’s equity was $1.02 billion (2022: $1.04 billion), representing a book value per share of $3.89 (2022: $3.96).
Analyst Certification – The views expressed in this research report accurately reflect the personal views of Mayberry Investments Limited Research Department about those issuer (s) or securities as at the date of this report. Each research analyst (s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation (s) or view (s) expressed by that research analyst in this research report.
Company Disclosure – The information contained herein has been obtained from sources believed to be reliable, however its accuracy and completeness cannot be guaranteed. You are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be unlawful. Mayberry may effect transactions or have positions in securities mentioned herein. In addition, employees of Mayberry may have positions and effect transactions in the securities mentioned herein